View in EDS HTML Full Text PDF Full Text

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.

Saved in:
Bibliographic Details
Title: CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
Authors: Pariser, David M.1 (AUTHOR), Lebwohl, Mark G.2 (AUTHOR), Jaworski, Janusz3 (AUTHOR), Trefler, Jakub4 (AUTHOR), Daniluk, Stefan5 (AUTHOR), Dudek, Anna6 (AUTHOR), Baran, Wojciech7 (AUTHOR), Owczarek, Witold8,9 (AUTHOR), Brzewski, Pawel10,11 (AUTHOR), Sikora, Mariusz12 (AUTHOR), Krogulec, Marek13 (AUTHOR), Kim, SungHyun14 (AUTHOR), Suh, JeeHye14 (AUTHOR), Choi, EunJin14 (AUTHOR), Cha, JungBin14 (AUTHOR), Lee, HyunJin14 (AUTHOR), Lee, SungJeong14 (AUTHOR), Koo, John Y.15 (AUTHOR) john.Koo2@ucsf.edu
Source: Dermatology & Therapy. May2025, Vol. 15 Issue 5, p1079-1092. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938210
DOI:10.1007/s13555-025-01383-5